Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer [Phase 2]
Phase 2 trial evaluating LY3537021 for chemotherapy-induced nausea and vomiting in adults with cancer; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide [Phase 2]
Phase 2 clinical trial assessing auricular point stimulation plus dexamethasone to prevent chemotherapy-induced nausea and vomiting in patie…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel [Phase 2]
A Phase 2 trial is evaluating auricular point stimulation plus dexamethasone to prevent chemotherapy-induced nausea and vomiting from gemcit…
-
FDA approval · 2026-04-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride, a generic antiemetic, with Onesource Specialty Pharma Limited as …
-
FDA approval · 2026-04-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited under ANDA078257.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens [Phase 3]
Phase 3 trial evaluating NEPA plus olanzapine with a dexamethasone-sparing strategy for chemotherapy-induced nausea and vomiting in patients…
-
FDA approval · 2026-04-08FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for ondansetron (generic) from West-Ward Pharmaceuticals Corp.
-
FDA approval · 2026-04-08FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
The FDA approved a supplemental application for ondansetron filed by West-Ward Pharmaceuticals Corp. This action updates the product’s regul…
-
FDA approval · 2026-04-03FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for Ondansetron submitted by PAI Holdings, LLC dba PAI Pharma (ANDA078127). This action confirms reg…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING [NA]
A completed clinical trial evaluated transcutaneous electrical acupoint stimulation for preventing nausea and vomiting caused by cisplatin c…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) [Phase 2]
Phase 2 clinical trial evaluating IV NEPA (fosnetupitant/palonosetron) for prevention of chemotherapy-induced nausea and vomiting in pediatr…
-
FDA approval · 2026-03-30FDA Approved: FOCINVEZ — Supplemental Application (Steriscience Specialties Private Limited)
The FDA approved a supplemental application for FOCINVEZ (fosaprepitant dimeglumine) submitted by Steriscience Specialties Private Limited.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children [NA]
A completed clinical trial evaluated athermic laser therapy stimulating acupuncture points to prevent chemotherapy-induced nausea and vomiti…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC [Phase 4]
Phase 4 exploratory trial evaluating the efficacy and safety of combining fosaprepitant and palonosetron hydrochloride to prevent chemothera…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer [NA]
A completed clinical trial evaluated whether meditation training can reduce chemotherapy‑induced nausea and vomiting in women with breast ca…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting [NA]
This clinical trial update describes evaluating relaxation breathing exercises to reduce chemotherapy-induced nausea and vomiting in patient…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Vomiting Prevention in Children With Cancer [NA]
A pediatric clinical trial is currently recruiting to evaluate vomiting prevention strategies for children undergoing chemotherapy to improv…
-
FDA approval · 2026-03-02FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride from Aurobindo Pharma Limited, confirming labeling for this generic an…
-
FDA approval · 2026-02-25FDA Approved: ONDANSETRON — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for a generic ondansetron hydrochloride product from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2026-02-23FDA Approved: SUSTOL — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for SUSTOL (granisetron) from Heron Therapeutics, Inc. This action expands its indication to prevent…
-
EMA approval · 2026-02-20EMA Authorised: Palonosetron Accord (palonosetron) — Accord Healthcare S.L.U.
The EMA authorised Palonosetron Accord (palonosetron) from Accord Healthcare S.L.U. for the prevention of nausea and vomiting in cancer pati…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
This clinical trial update describes a planned network meta-analysis comparing different olanzapine dose regimens for preventing chemotherap…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy [Phase 2]
This clinical trial update describes a Phase 2 study evaluating medical cannabis for chemotherapy-induced nausea and vomiting, currently not…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients [NA]
This clinical trial is evaluating whether foot reflexology can reduce chemotherapy-induced nausea and vomiting in breast cancer patients, wi…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT) [NA]
This study is evaluating the feasibility and acceptability of inhaled aromatherapy for patients undergoing autologous haematopoietic stem ce…